🇺🇸 FDA
Patent

US 11981739

Chimeric antigen receptor specific for interleukin-23 receptor

granted A61KA61K2039/505A61K2239/31

Quick answer

US patent 11981739 (Chimeric antigen receptor specific for interleukin-23 receptor) held by SANGAMO THERAPEUTICS FRANCE expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SANGAMO THERAPEUTICS FRANCE
Grant date
Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K40/11